Analytical Data
-
Gene name
TCL6
- Application
-
Alternative Names
TCL6e1; TNG2; TNG1
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9P2S0
-
Expression Region
Met1~Arg163
-
Molecular Weight
22kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TCL6, a member of the T-cell leukemia 6 (TCL6) gene family, has garnered considerable attention in recent years due to its potential role in various biological processes, including immune response and cellular development. Discovered as a gene expressed in activated T cells, TCL6 has been implicated in the regulation of gene expression and may serve as a critical factor in T-cell activation and differentiation. The study of TCL6 recombinant proteins aims to elucidate its functional mechanisms and interactions within the immune system. Researchers have been focusing on producing and characterizing TCL6 recombinant proteins to better understand their structural properties and biological activities. This research is vital not only for advancing our understanding of immune modulation but also for developing novel therapeutic strategies, especially in the context of immunological diseases and cancers. Moreover, the recombinant form of TCL6 can be utilized as a potential biomarker for diagnostic purposes and in the design of targeted therapies. As the investigation of TCL6 continues to unfold, it opens up new avenues for exploring its implications in both health and disease, underscoring the importance of detailed biophysical and functional analyses of this intriguing protein.
